Billionaire Larry Robbins’ 10 Dividend Stock Picks

8. Danaher Corporation (NYSE:DHR)

Glenview Capital’s Stake Value: $29,629,740

On June 11, Piper Sandler initiated coverage of Danaher Corporation (NYSE:DHR) with a Neutral rating and a $200 price target. The firm launched coverage of the life science tools sector with what it described as a “feet in the shallow end of the pool” approach. Among the companies under coverage, Piper only recommends buying Twist Bioscience, citing its growing exposure to next-generation drug discovery and development.

According to the analyst, headwinds related to biotech and academic spending, along with China exposure, are likely to improve in the near term. Even so, Piper wants to see some of the next major growth drivers emerge before recommending more stocks in the sector. The firm argues that investors “can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-COVID.”

Danaher Corporation (NYSE:DHR) is a global life sciences and diagnostics innovator. The company operates through three segments: Biotechnology, Life Sciences, and Diagnostics.